Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration

BMC Cancer

Research Article

Zonggao Shi¹  Sunil Badve²  Ayub Ofulla³  David Chumba⁴  Kirtika Patel⁴  Simeon Mining⁴  Katherine Taylor⁵  Mayra Sandoval-Cooper⁶  Jun Li⁶  Maggie Kerper⁶  Jingmeng Xie⁷  Laurie E. Littlepage⁸  M. Sharon Stack⁸  Jenifer Prosperi⁹  Rispah T. Sawe^1,10 

[1] Harper Cancer Research Institute, University of Notre Dame, 1234 N Notre Dame Avenue, South Bend, IN, USA;Harper Cancer Research Institute, University of Notre Dame, 1234 N Notre Dame Avenue, South Bend, IN, USA;Indiana University School of Medicine, Indianapolis, IN, USA;Maseno University, Maseno, Kenya;Moi University, Eldoret, Kenya;University of Notre Dame, Notre Dame, IN, USA;Eck Institute for Global Health, Notre Dame, IN, USA;University of Notre Dame, Notre Dame, IN, USA;Harper Cancer Research Institute, University of Notre Dame, 1234 N Notre Dame Avenue, South Bend, IN, USA;University of Notre Dame, Notre Dame, IN, USA;Harper Cancer Research Institute, University of Notre Dame, 1234 N Notre Dame Avenue, South Bend, IN, USA;Eck Institute for Global Health, Notre Dame, IN, USA;University of Notre Dame, Notre Dame, IN, USA;Harper Cancer Research Institute, University of Notre Dame, 1234 N Notre Dame Avenue, South Bend, IN, USA;Indiana University School of Medicine, Indianapolis, IN, USA;University of Notre Dame, Notre Dame, IN, USA;Harper Cancer Research Institute, University of Notre Dame, 1234 N Notre Dame Avenue, South Bend, IN, USA;Indiana University School of Medicine, Indianapolis, IN, USA;Indiana University School of Medicine-South Bend, South Bend, IN, USA;University of Notre Dame, Notre Dame, IN, USA;Harper Cancer Research Institute, University of Notre Dame, 1234 N Notre Dame Avenue, South Bend, IN, USA;Moi University, Eldoret, Kenya;Maseno University, Maseno, Kenya;

关键词: Kenya;    Breast cancer;    Estrogen receptor;    CD163;    CD25;   

DOI  :  10.1186/s12885-016-2204-6

 received in 2015-11-29, accepted in 2016-02-17,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundBreast cancer incidence and mortality vary significantly among different nations and racial groups. African nations have the highest breast cancer mortality rates in the world, even though the incidence rates are below those of many nations. Differences in disease progression suggest that aggressive breast tumors may harbor a unique molecular signature to promote disease progression. However, few studies have investigated the pathology and clinical markers expressed in breast tissue from regional African patient populations.MethodsWe collected 68 malignant and 89 non-cancerous samples from Kenyan breast tissue. To characterize the tumors from these patients, we constructed tissue microarrays (TMAs) from these tissues. Sections from these TMAs were stained and analyzed using immunohistochemistry to detect clinical breast cancer markers, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 receptor (HER2) status, Ki67, and immune cell markers.ResultsThirty-three percent of the tumors were triple negative (ER-, PR-, HER2-), 59 % were ER+, and almost all tumors analyzed were HER2-. Seven percent of the breast cancer patients were male, and 30 % were <40 years old at diagnosis. Cancer tissue had increased immune cell infiltration with recruitment of CD163+ (M2 macrophage), CD25+ (regulatory T lymphocyte), and CD4+ (T helper) cells compared to non-cancer tissue.ConclusionsWe identified clinical biomarkers that may assist in identifying therapy strategies for breast cancer patients in western Kenya. Estrogen receptor status in particular should lead initial treatment strategies in these breast cancer patients. Increased CD25 expression suggests a need for additional treatment strategies designed to overcome immune suppression by CD25+ cells in order to promote the antitumor activity of CD8+ cytotoxic T cells.

【 授权许可】

CC BY   
© Sawe et al. 2016

【 图 表 】

12864_2017_3898_Article_IEq4.gif